Roche Servicios S.A.
Business Opportunity Assessment Report

Company Snapshot

Roche Servicios S.A. is a Uruguay-based commercial entity registered at Parque Industrial Ultrapark, Heredia, Costa Rica — indicating a cross-border operational footprint with legal presence in Uruguay and physical logistics infrastructure in Costa Rica’s industrial park. Its core activity centers on the import and distribution of pharmaceutical and diagnostic products, functioning primarily as a regional supply chain intermediary for life sciences goods. Structurally, it exhibits high transactional concentration — over 96% of trade activity is directed to Costa Rica, and nearly 91% of shipments clear through Aduana Santa Maria. A notable signal is the sharp volume surge in mid-2024 (e.g., 4.28M units in May 2024), followed by stabilization at ~100–200K/month since early 2025, suggesting a post-scaling consolidation phase.

Company Attributes

Trade Trend Analysis

Data解读: Transaction volume shows extreme volatility — a single month (May 2024) accounts for >35% of total 3-year volume, followed by a steep normalization to ~100–200K units/month. Frequency remains consistently high (300–700 transactions/month), indicating recurring small-batch procurement rather than project-based bulk imports. The absence of seasonal patterns and persistent activity across all months suggest operational continuity, not campaign-driven demand. This pattern reflects inventory ramp-up or regulatory stockpiling followed by steady-state replenishment logistics.

Trade Partner Analysis

Data解读: Over 90% of transactions are self-referential — labeled as "roche servicios s.a." — indicating internal group transfers or intra-company logistics coordination. The second-largest counterparty ("not specified") accounts for another 8.7%, reinforcing opacity in consignee identification. All other partners represent <0.1% each, with most having only 1–2 transactions and no recent activity — suggesting minimal third-party commercial engagement. This structure signals a tightly controlled, vertically aligned distribution network rather than an open-market trading model.

HS Code Analysis

Data解读: Two HS codes dominate — 3002150000 (diagnostic reagents) and 3004909100 (pharmaceutical preparations) — collectively representing 66% of all transactions. Their dual “maintained/lost” status across variants (e.g., 3002150000 vs. 300215000000) suggests classification granularity tied to packaging, dosage, or regulatory sub-categorization. Notably, all top-10 HS codes fall under Chapter 30 (Pharmaceutical Products), confirming strict domain focus with zero diversification into devices or equipment. This reinforces a narrow, compliance-sensitive specialization in regulated health product categories.

Trade Region Analysis

Data解读: Costa Rica dominates with 96.8% of transaction count — far exceeding its share of global pharmaceutical imports — implying Roche Servicios S.A. serves as a dedicated regional hub, likely supporting local Roche affiliates or licensed distributors. Switzerland and Netherlands appear as minor but newly active partners (2025), possibly linked to EU regulatory supply chains or API sourcing. The near-total absence of trade with major pharma markets (US, Germany, UK) outside of 1–2 isolated entries confirms a hyper-regionalized role. This geographic confinement underscores low export ambition and high dependency on Central American market access.

Export Port Analysis

Data解读: Aduana Santa Maria handles 90.7% of all shipments — a customs facility located in Costa Rica — confirming that operations are physically anchored there despite Uruguayan registration. The secondary port "santamaria" (likely same location, alternate naming) accounts for another 9.1%, while all others are negligible (<0.2%). This near-total port concentration eliminates logistical fragmentation and implies standardized clearance protocols, likely optimized for time-sensitive health products. This port dominance reflects full operational integration within Costa Rica’s customs ecosystem.

Contact Information

No official website, social media profiles (LinkedIn, Facebook, Twitter), email, phone number, or press releases were found via public search. No corporate registry or industry report references available. Contact details remain unverifiable from open sources.

Company Trade Summary

• Operates as a Costa Rica–based distribution arm under Uruguayan legal registration.
• Exclusively focused on Chapter 30 pharmaceuticals — especially diagnostic reagents (HS 300215) and finished formulations (HS 300490).
• 96.8% of trade is domestic (Costa Rica), with no evidence of active export development.
• Transactional structure is dominated by intra-group flows (>90%), not third-party B2B commerce.
• Zero digital footprint — no verifiable online presence, limiting due diligence and outreach viability.